KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results